The job market is undergoing a transformation in 2025, with the evolutions of previous years accelerated by significant ...

In April 2022, the company also announced it was halting the development of three gene therapy candidates for Duchenne muscular dystrophy (DMD). AT845 uses the same AAV8 capsid platform as AT132 ...